⚠️ GLP-1 Nausea Vomiting Titration Mitigation Simulator

Standard Dose Start & Baseline Risk

Starting dose sets baseline nausea risk before any mitigation.

• 0.25 mg: Starting dose (lowest titration tier)
• ~44%: Nausea incidence (fast start) (reported in trials)
• ~15%: Vomiting incidence (without titration)
• Week 1–2: Typical onset (after first dose)

Why nausea spikes early

Delayed gastric emptying triggers early GI discomfort.

Fast titration roughly doubles early nausea incidence.

Dose-dependent risk

Higher starting doses raise nausea and vomiting rates.

Individual variability

Genetics and gut motility shape symptom severity.

Mitigation Strategies Introduced

Four practical tactics blunt the nausea curve.

• +4 wks: Slow titration (per dose step)
• -30%: Meal size (smaller, frequent meals)
• Reduced: Low-fat diet (delayed emptying trigger)
• 20+ min: Eating pace (per meal recommended)

Slow titration

Extending time between dose increases lowers peak nausea.

Slow titration alone can cut peak severity by ~30%.

Smaller, frequent meals

Reduces gastric volume load per sitting.

Low-fat, slow eating

Both reduce delayed gastric emptying discomfort.

Nausea Risk Curve — With vs Without Mitigation

Side-by-side curves show mitigation flattening the spike.

• ~8.4/10: Peak severity (fast, no mitigation) (week 1 spike)
• ~3.5/10: Peak severity (full mitigation) (week 2–3 spike)
• ~4–6 wks: Time to resolution (mitigated) (back to baseline)
• ~8–10 wks: Time to resolution (unmitigated) (slower decline)

Curve shape

Both curves spike then decay; mitigation lowers and shortens the spike.

Combining all four strategies roughly halves peak severity.

Comparative decline rate

Mitigated curves decay faster after their lower peak.

Clinical relevance

Flatter curves improve adherence and reduce discontinuation.

GI Symptom Trend Over Weeks

Tachyphylaxis: GI side effects fade as the body adapts.

• 3–4 wks: Median weeks to improvement (with mitigation)
• ~80%: Patients improving by week 8 (across trials)
• ~5–7%: Discontinuation due to GI effects (overall rate)
• Receptor: Adaptation mechanism (desensitization over time)

Tachyphylaxis

Repeated exposure blunts the GI signaling response.

Symptom trend typically flips from worsening to improving by week 3.

Tracking trend

Weekly symptom scores reveal the decline pattern.

Reinforcing habits

Continued mitigation speeds the adaptation window.

Resolution or Dose Reduction

Most nausea resolves; persistent cases signal dose review.

• ~85–90%: Full resolution rate (within 8–12 weeks)
• ~10–15%: Dose reduction needed (persistent severe cases)
• ~70%: Re-titration success (after slower restart)
• High: Long-term GI tolerance (once maintenance reached)

Expected resolution

Nausea typically resolves within weeks with proper mitigation.

Persistent severe nausea past 8 weeks warrants a dose-reduction discussion.

When to step back

Severe, non-improving symptoms flag a slower re-titration.

Maintenance outlook

Tolerance at the maintenance dose is generally durable.